Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

[1] Lindeman NI(2013)Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Mol Diagn: JMD 15 415-453

[2] Cagle PT(2011)Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society—abridged version Pneumologie 65 e51-e75

[3] Beasley MB(2014)Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations PLoS One 9 e85245-238

[4] Chitale DA(2014)Afatinib in the treatment of EGFR mutation-positive NSCLC—a network meta-analysis Lung Cancer (Amst, Neth) 85 230-105

[5] Dacic S(2014)First-line treatment of EGFR-mutated non-small cell lung cancer: critical review on study methodology Eur Respir Rev 23 92-198

[6] Giaccone G(2006)Biological and clinical implications of EGFR mutations in lung cancer Int J Clin Oncol 11 190-1828

[7] Goeckenjan G(2013)EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice Br J Cancer 109 1821-455

[8] Sitter H(2014)Is individualized medicine more cost-effective? A systematic review Pharmacoeconomics 32 443-1039

[9] Thomas M(2014)A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) BMC Pulm Med 14 192-27

[10] Branscheid D(2012)Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung Cancer 118 1032-274

[1] Lindeman NI(2013)Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Mol Diagn: JMD 15 415-453

[2] Cagle PT(2011)Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society—abridged version Pneumologie 65 e51-e75

[3] Beasley MB(2014)Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations PLoS One 9 e85245-238

[4] Chitale DA(2014)Afatinib in the treatment of EGFR mutation-positive NSCLC—a network meta-analysis Lung Cancer (Amst, Neth) 85 230-105

[5] Dacic S(2014)First-line treatment of EGFR-mutated non-small cell lung cancer: critical review on study methodology Eur Respir Rev 23 92-198

[6] Giaccone G(2006)Biological and clinical implications of EGFR mutations in lung cancer Int J Clin Oncol 11 190-1828

[7] Goeckenjan G(2013)EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice Br J Cancer 109 1821-455

[8] Sitter H(2014)Is individualized medicine more cost-effective? A systematic review Pharmacoeconomics 32 443-1039

[9] Thomas M(2014)A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) BMC Pulm Med 14 192-27

[10] Branscheid D(2012)Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung Cancer 118 1032-274